Immunotoxins: all 376 studies that test it
Page 4 of 4. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.
- Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.CompletedNCT02227433Phase 2
- Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLCompletedNCT02182596Phase 1/2
- Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
- Patients With Brain Metastases From HER2-positive Breast CancerCompletedNCT02135159Phase 1
- SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
- Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCompletedNCT02073916Phase 1
- A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedNCT01983501Phase 1
- Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)CompletedNCT01976169Phase 1
- Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.CompletedNCT01975142Phase 2
- Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)TerminatedNCT01940796Phase 1
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
- Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
- Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01891981Phase 1
- Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsCompletedNCT01851200Phase 2
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT01816035Phase 1
- A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.CompletedNCT01745965Phase 2
- Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
- Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyWithdrawnNCT01671813Not applicable
- Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesWithdrawnNCT01620229Phase 1/2
- Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host DiseaseWithdrawnNCT01616680Phase 2
- Brentuximab Vedotin for Steroid Refractory GvHDCompletedNCT01596218Phase 1
- HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1CompletedNCT01565200Phase 2
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
- Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
- Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphomaCompletedNCT01535989Phase 1
- A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic FunctionCompletedNCT01513083Phase 1
- SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
- LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
- Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
- Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedNCT00991562Phase 1
- Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1
- Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2
- Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00717925Phase 1
- Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid LeukemiaTerminatedNCT00660036Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00587015Phase 1
- Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
- Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance DiseaseStatus unknownNCT00515892Phase 1
- NOPHO-AML 2004 Study for Children With Acute Myeloid LeukemiaCompletedNCT00476541Phase 3
- Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance DiseaseStatus unknownNCT00462189Phase 1
- Gemtuzumab Ozogamicin Before Allogeneic Stem Cell TransplantationStatus unknownNCT00460447Phase 1/2
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance DiseaseStatus unknownNCT00457860Phase 1
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
- BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00346385Phase 1
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT00346255Phase 1
- Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
- A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaCompletedNCT00233909Phase 1/2
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaStatus unknownNCT00091234Phase 2/3
- Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00089050Phase 2
- Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
- Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification TherapyCompletedNCT00070174Phase 2
- Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00052299Phase 3
- S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00049179Phase 2
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell TransplantCompletedNCT00044733Phase 2
- Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSCompletedNCT00038831Phase 1/2
- Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)TerminatedNCT00038805Phase 2/3
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaCompletedNCT00037596Phase 2
- Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaCompletedNCT00037583Phase 2
- Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00028899Phase 1
- Gemtuzumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT00022321Phase 2
- Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
- Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00008151Phase 2
- Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00006122Phase 2